The QPPV function plays a pivotal role in ensuring the continuous and compliant operation of a sponsor's pharmacovigilance (PV) system. The QPPV office maintains end-to-end oversight of the PV framework, ensuring regulatory compliance, operational continuity, and ongoing evaluation of the benefit-risk profile of medicinal products.
Serving as the 24/7 single point of contact for competent authorities, the QPPV is supported by a designated Backup QPPV to ensure uninterrupted coverage at all times. Together, they oversee PV system performance and ensure that safety concerns are promptly identified, assessed, and addressed to safeguard patient well-being.
CareLyft offers experienced UK and EU QPPV services, delivered by senior pharmacovigilance professionals based in the UK and Croatia. Our structure includes clearly segregated roles:
This model ensures full alignment with MHRA and EMA regulatory expectations. Additionally, we provide a dedicated Responsible Person for EudraVigilance (RPEV) to support EU clinical trial safety reporting obligations.
Certain jurisdictions require the appointment of a Local QPPV or National Contact Person for Pharmacovigilance (NCPP) in addition to the global QPPV. CareLyft supports these requirements through a strong network of trusted local partners across 35+ countries, enabling seamless regional and country-specific compliance.
For UK-based requirements, we also offer a National Contact Person service as an alternative to appointing a separate UK QPPV, depending on client preference and regulatory strategy.